Stealth BioTherapeutics Corp. announced that Vincent Sai Sing Cheung and Cheuk Kin Stephen Law resigned as members of the Board of Directors, effective immediately. the Board appointed Louis Lange, M.D., Ph.D as a Class II director and as a member of the Audit Committee and Remuneration Committee, effective as of July 24, 2019. Dr. Lange is currently a general partner at Asset Management Ventures, an investment firm, where he has worked since June 2009. Dr. Lange was the co-founder and served as the President and Chief Executive Officer of Cardiogen Sciences Inc. in August 2015. Dr. Lange also co-founded CV Therapeutics Inc. in 1990 and served as the Chairman, Chief Executive Officer and Chief Scientific Officer until it was acquired by Gilead Sciences Inc. in 2009. Dr. Lange has also served as the Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University. Dr. Lange has served as a member of Audentes Therapeutics Inc.’s board of directors since August 2015 and served on the board of directors of Maxygen Inc. from December 2005 to August 2013, CymaBay Therapeutics Inc. from November 2003 to October 2015, and Esperion Therapeutics Inc. from February 2010 to May 2014. Dr. Lange also serves as a member of the Board of Trustees at the University of Rochester, The Gladstone Foundation, is a senior advisor to Gilead and was on the board of directors of BIO from 1998 to 2009, as well as other private companies. Dr. Lange holds a B.A. from the University of Rochester, an M.D. from Harvard Medical School and a Ph.D. from Harvard University.